Lupin has received approval for its Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg from the United States Food and Drug Administration (USFDA) to market a generic version of SpecGx LLC's Anafranil Capsules, 25 mg, 50 mg, and 75 mg.
Lupin's Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg is the generic version of SpecGx LLC's Anafranil Capsules, 25 mg, 50 mg, and 75 mg. It is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).
Anafranil Capsules, 25 mg, 50 mg, and 75 mg had annual sales of approximately $109.6 million in the US (IQVIA MAT September 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
